This study more comprehensively examined the expression of dysadherin in different types of thyroid pathologies and assessed the potential for EDC1 as a treatment for aggressive thyroid cancers by evaluating the efficacy of EDC1 on human thyroid cancer lines. Here, FXYD5 is linked to thyroiditis.